Research ExplorerPublicationsHematopoietic stem and progenitor cell mobilization in mice ...

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12

Standard

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. / Vater, A; Sahlmann, J; Kröger, N; Zöllner, S; Lioznov, M; Maasch, C; Buchner, K; Vossmeyer, D; Schwoebel, F; Purschke, W G; Vonhoff, S; Kruschinski, A; Hübel, K; Humphrey, M; Klussmann, S; Fliegert, F.

In: CLIN PHARMACOL THER, Vol. 94, No. 1, 01.07.2013, p. 150-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Vater, A, Sahlmann, J, Kröger, N, Zöllner, S, Lioznov, M, Maasch, C, Buchner, K, Vossmeyer, D, Schwoebel, F, Purschke, WG, Vonhoff, S, Kruschinski, A, Hübel, K, Humphrey, M, Klussmann, S & Fliegert, F 2013, 'Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12', CLIN PHARMACOL THER, vol. 94, no. 1, pp. 150-7. https://doi.org/10.1038/clpt.2013.58

APA

Vater, A., Sahlmann, J., Kröger, N., Zöllner, S., Lioznov, M., Maasch, C., Buchner, K., Vossmeyer, D., Schwoebel, F., Purschke, W. G., Vonhoff, S., Kruschinski, A., Hübel, K., Humphrey, M., Klussmann, S., & Fliegert, F. (2013). Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. CLIN PHARMACOL THER, 94(1), 150-7. https://doi.org/10.1038/clpt.2013.58

Vancouver

Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. CLIN PHARMACOL THER. 2013 Jul 1;94(1):150-7. https://doi.org/10.1038/clpt.2013.58

Bibtex

@article{6e80210c2e7247e089e175ea40f875e1,
title = "Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12",
abstract = "NOX-A12 is a PEGylated mirror-image oligonucleotide (a so-called Spiegelmer) that binds to CXCL12 (stromal cell-derived factor-1, SDF-1) with high affinity thereby inhibiting CXCL12 signaling on both its receptors, CXCR4 and CXCR7. In animals, NOX-A12 mobilized white blood cells (WBCs) and hematopoietic stem and progenitor cells (HSCs) into peripheral blood (PB). In healthy volunteers, single doses of NOX-A12 had a benign safety profile and also dose-dependently mobilized WBCs and HSCs into PB. HSC peak mobilization reached a plateau at five times the baseline level at an i.v. dose of 5.4 mg/kg. In accordance with the plasma half-life of 38 h, the duration of the WBC and HSC mobilization was long lasting and increased dose-dependently to more than 4 days at the highest dose (10.8 mg/kg). In conclusion, NOX-A12 may be appropriate for therapeutic use in and beyond mobilization of HSCs, e.g., in long-lasting mobilization and chemosensitization of hematological cancer cells.",
keywords = "Adolescent, Adult, Animals, Chemokine CXCL12, Dose-Response Relationship, Drug, Female, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells, Humans, Leukocyte Count, Leukocytes, Macaca, Male, Mice, Middle Aged, Models, Animal, Oligonucleotides, Young Adult",
author = "A Vater and J Sahlmann and N Kr{\"o}ger and S Z{\"o}llner and M Lioznov and C Maasch and K Buchner and D Vossmeyer and F Schwoebel and Purschke, {W G} and S Vonhoff and A Kruschinski and K H{\"u}bel and M Humphrey and S Klussmann and F Fliegert",
year = "2013",
month = jul,
day = "1",
doi = "10.1038/clpt.2013.58",
language = "English",
volume = "94",
pages = "150--7",
journal = "CLIN PHARMACOL THER",
issn = "0009-9236",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12

AU - Vater, A

AU - Sahlmann, J

AU - Kröger, N

AU - Zöllner, S

AU - Lioznov, M

AU - Maasch, C

AU - Buchner, K

AU - Vossmeyer, D

AU - Schwoebel, F

AU - Purschke, W G

AU - Vonhoff, S

AU - Kruschinski, A

AU - Hübel, K

AU - Humphrey, M

AU - Klussmann, S

AU - Fliegert, F

PY - 2013/7/1

Y1 - 2013/7/1

N2 - NOX-A12 is a PEGylated mirror-image oligonucleotide (a so-called Spiegelmer) that binds to CXCL12 (stromal cell-derived factor-1, SDF-1) with high affinity thereby inhibiting CXCL12 signaling on both its receptors, CXCR4 and CXCR7. In animals, NOX-A12 mobilized white blood cells (WBCs) and hematopoietic stem and progenitor cells (HSCs) into peripheral blood (PB). In healthy volunteers, single doses of NOX-A12 had a benign safety profile and also dose-dependently mobilized WBCs and HSCs into PB. HSC peak mobilization reached a plateau at five times the baseline level at an i.v. dose of 5.4 mg/kg. In accordance with the plasma half-life of 38 h, the duration of the WBC and HSC mobilization was long lasting and increased dose-dependently to more than 4 days at the highest dose (10.8 mg/kg). In conclusion, NOX-A12 may be appropriate for therapeutic use in and beyond mobilization of HSCs, e.g., in long-lasting mobilization and chemosensitization of hematological cancer cells.

AB - NOX-A12 is a PEGylated mirror-image oligonucleotide (a so-called Spiegelmer) that binds to CXCL12 (stromal cell-derived factor-1, SDF-1) with high affinity thereby inhibiting CXCL12 signaling on both its receptors, CXCR4 and CXCR7. In animals, NOX-A12 mobilized white blood cells (WBCs) and hematopoietic stem and progenitor cells (HSCs) into peripheral blood (PB). In healthy volunteers, single doses of NOX-A12 had a benign safety profile and also dose-dependently mobilized WBCs and HSCs into PB. HSC peak mobilization reached a plateau at five times the baseline level at an i.v. dose of 5.4 mg/kg. In accordance with the plasma half-life of 38 h, the duration of the WBC and HSC mobilization was long lasting and increased dose-dependently to more than 4 days at the highest dose (10.8 mg/kg). In conclusion, NOX-A12 may be appropriate for therapeutic use in and beyond mobilization of HSCs, e.g., in long-lasting mobilization and chemosensitization of hematological cancer cells.

KW - Adolescent

KW - Adult

KW - Animals

KW - Chemokine CXCL12

KW - Dose-Response Relationship, Drug

KW - Female

KW - Hematopoietic Stem Cell Mobilization

KW - Hematopoietic Stem Cells

KW - Humans

KW - Leukocyte Count

KW - Leukocytes

KW - Macaca

KW - Male

KW - Mice

KW - Middle Aged

KW - Models, Animal

KW - Oligonucleotides

KW - Young Adult

U2 - 10.1038/clpt.2013.58

DO - 10.1038/clpt.2013.58

M3 - SCORING: Journal article

C2 - 23588307

VL - 94

SP - 150

EP - 157

JO - CLIN PHARMACOL THER

JF - CLIN PHARMACOL THER

SN - 0009-9236

IS - 1

ER -